How much dividend does Bionomics pay?
Over the past 12 months, Bionomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bionomics is expected to pay a dividend of 0 AUD.
Bionomics Dividend 2025
Bionomics Dividend
0 AUD
Bionomics Dividend yield
Ticker
BNO.AX
ISIN
AU000000BNO5
WKN
936199
How much dividend does Bionomics 2025 pay?
According to the latest status from June 2025, Bionomics paid a total of 0 AUD per share in dividends within the last 12 months. With the current Bionomics price of 0.01 AUD, this corresponds to a dividend yield of 0 %. A dividend is paid times per year.
| = |
Historical Bionomics Dividends
A dividend is paid times per year. Last year, the payout months were and .
| Paydate | Dividend |
|---|
Is the Bionomics Dividend Safe?
Bionomics has been increasing the dividend for 0 years.
Over the past 10 years, Bionomics has increased it by an annual 0 %.
Over a five-year period, the distribution increased by 0%.
Analysts expect a Dividend Cut of -100% for the current fiscal year.
Dividend Details
Understanding Bionomics's Dividend Distributions
Bionomics’s dividends are a portion of the company’s profits distributed to shareholders. It is a critical indicator of the company’s financial health and attractiveness to investors. Dividends provide investors with a steady income stream, in addition to any profits that may come from selling the stock at a higher price than the purchase price.
Year-to-Year Comparison
Examining Bionomics's dividend distributions over the years can highlight the company’s profitability and stability. A consistent or increasing dividend payout can indicate a financially healthy company with predictable earnings, while fluctuations or reductions in dividends can suggest underlying financial or operational challenges.
Impact on Investments
Bionomics's dividend payments are an essential factor for income-focused investors. A robust dividend payout can enhance the stock’s appeal, offering regular income in addition to potential capital gains. It also can indicate the company's confidence in its future earnings, making it a significant consideration in investment decisions.
Interpreting Dividend Fluctuations
Changes in Bionomics’s dividends can result from shifts in the company’s earnings, financial policies, or reinvestment strategies. An increase in dividends often signals financial stability, while a decrease may indicate a need to conserve cash or reinvest profits to fuel growth, each scenario having different implications for investors.
Bionomics Aktienanalyse
What does Bionomics do?
Bionomics Ltd is an Australian biopharmaceutical company specializing in the development of novel therapeutics for the treatment of diseases of the central nervous system and cancer. The company is headquartered in Adelaide, South Australia, and has offices and research facilities in the United States and France. Bionomics was founded in 1998 by Dr. Deborah Rathjen, an experienced biotechnology manager and scientist. The company started as a spin-off from Flinders University in Adelaide, focusing initially on the discovery and development of drug candidates based on novel peptides. In 2002, Bionomics went public, gaining access to capital to expand its research activities and adjust its business strategy. Bionomics operates an integrated pharmaceutical model, ranging from the discovery and optimization of novel therapeutic targets and drugs to clinical development and market launch of pharmaceuticals. The company develops innovative technologies, including the MultiCore platform, to develop peptide-based drugs. Bionomics has two main divisions: CNS therapy and cancer therapy. The CNS therapy division focuses on the development of drugs for the treatment of central nervous system disorders, including schizophrenia, depression, anxiety disorders, neuropathic pain, spinal cord injuries, and other disorders. Bionomics is currently conducting clinical trials to evaluate the effectiveness of its leading drug candidates BN311 and BNO69 in the treatment of depression and anxiety disorders. Bionomics' cancer therapy division focuses on the discovery and development of drug candidates for the treatment of cancer. The company has identified a number of leading preclinical drug candidates based on novel targets, showing promising results in the treatment of breast, lung, ovarian, liver cancer, and other types of cancer. Bionomics has a range of products in development or in clinical stages. The company's leading product is BN311, a drug candidate for the treatment of depression based on Bionomics' MultiCore technology. BN311 has shown efficacy in preclinical studies in the treatment of depression and anxiety disorders and is currently being tested in a phase II clinical trial. BNO69 is another drug candidate from Bionomics based on the same technology. The candidate has been developed for the treatment of anxiety disorders and shows great promise. It has proven effective in preclinical studies and has the potential to revolutionize the treatment of anxiety disorders. The company is also developing drug candidates for the treatment of cancer, including BNC101, BNC105, BNC211, and BNC375. All of these drug candidates are based on novel targets and have shown promising results in preclinical studies. BNC375, a cancer immunotherapy, shows particularly promising results, and the company plans to conduct a phase I clinical trial to evaluate the efficacy of the drug in treating patients with advanced cancer. Overall, Bionomics Ltd is an emerging biopharmaceutical company specializing in the development of new and promising therapeutics for the treatment of diseases of the central nervous system and cancer. Bionomics has developed an integrated pharmaceutical model that supports innovation from discovery to commercialization and has a promising pipeline of drug candidates for the next generation of medications. Bionomics is one of the most popular companies on Eulerpool.com.Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Frequently Asked Questions about Bionomics stock
What is the dividend yield of Bionomics?
The current dividend yield of Bionomics is .
When does Bionomics pay dividends?
Bionomics pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Bionomics?
Bionomics paid dividends every year for the past 0 years.
What is the dividend of Bionomics?
For the upcoming 12 months, dividends amounting to 0 AUD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Bionomics located?
Bionomics is assigned to the 'Health' sector.
Wann musste ich die Aktien von Bionomics kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Bionomics from 6/9/2025 amounting to 0 AUD, you needed to have the stock in your portfolio before the ex-date on 6/9/2025.
When did Bionomics pay the last dividend?
The last dividend was paid out on 6/9/2025.
What was the dividend of Bionomics in the year 2024?
In the year 2024, Bionomics distributed 0 AUD as dividends.
In which currency does Bionomics pay out the dividend?
The dividends of Bionomics are distributed in AUD.
Andere Kennzahlen von Bionomics
Our stock analysis for Bionomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Bionomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
